Having trouble accessing articles? Reset your cache.

Aftermarket pop for 89bio following delayed IPO

NASH company 89bio may have been late to the market in pricing its IPO, but the biotech managed to upsize its offering while pricing at the midpoint of its proposed range. Demand persisted in Monday’s session, when its shares climbed

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers